IMUNON Presents PlaCCine Preclinical Data at the 2023 Viruses and Cells – Gordon Research Conference
2023年5月30日 - 9:00PM
IMUNON, Inc.
(NASDAQ: IMNN), a clinical-stage
drug-development company focused on developing non-viral
DNA-mediated immunotherapy and next-generation vaccines, announces
that Khursheed Anwer, Ph.D., the company’s Executive Vice President
and Chief Science Officer, presented new PlaCCine preclinical data
at the 2023 Viruses and Cells – Gordon Research Conference in
Barcelona. Dr. Khursheed’s presentation, titled “A Novel DNA
Vaccine Approach to Prophylactic and Therapeutic Vaccines,” was
delivered on May 25, 2023, and described IMUNON’S PlaCCine
technology platform for the development of next-generation
vaccines. Dr. Anwer’s presentation is available
[
here].
Results from preclinical studies in a PlaCCine
COVID-19 vaccine demonstrated characteristics that address the
limitations of current commercial vaccines by offering enhanced
breadth of protection to emerging variants, persistence and robust
cellular immunity, as well as stability at workable temperatures.
Importantly, humoral immune responses specific to the SARS-CoV-2
spike antigen were persistent over a 14-month post-vaccination
period in mice, while the T-cell responses from PlaCCine COVID-19
vaccines after 14 months were higher than a commercial mRNA
vaccine.
In another mouse study, the humoral response to
a single dose of a commercial mRNA vaccine plateaued within 14 days
after vaccination while the response continued to increase over
time with a PlaCCine vaccine, demonstrating improved durability. In
addition, PlaCCine was stable for at least eight months at
refrigerated temperatures and for at least one month at room
temperature.
Dr. Corinne Le Goff, President and Chief
Executive Officer of IMUNON, said, “These preclinical findings
underscore the potential of our PlaCCine platform to produce
next-generation COVID-19 vaccines that address the limitations of
the current commercial products. We are delighted the data continue
to show greater durability of response, which is vitally important
as we experience vaccine fatigue in populations asked to be
inoculated multiple times a year. In addition, our plug-and-play
approach permitting the design and development of vaccines to new
variants or targets within three months from receipt of antigen
sequences bodes well for our program as we identify new target
pathogens. In the meantime, we continue to advance
pre-Investigational New Drug activities and expect to file an IND
with the U.S. Food and Drug Administration for our SARS-CoV-2
proof-of-concept vaccine, with Phase 1 studies expected to begin in
early 2024.”
About IMUNON
IMUNON is a fully integrated, clinical stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective and durable responses across a broad array
of human diseases, constituting a differentiating approach from
conventional therapies.
IMUNON has two platform technologies: the
TheraPlas modality for the development of immunotherapies and other
anti-cancer nucleic acid-based therapies, and the PlaCCine modality
for the development of nucleic acid vaccines for infectious
diseases and cancer. The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer-fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
conducting preclinical proof-of-concept studies on a nucleic acid
vaccine candidate targeting the SARS-CoV-2 virus to validate its
PlaCCine platform. IMUNON’s platform technologies are based on the
delivery of nucleic acids with novel synthetic delivery systems
that are independent of viral vectors or devices. IMUNON will
continue to leverage these platforms and to advance the
technological frontier of nucleic acid-based products to better
serve patients with difficult-to-treat conditions. For more
information on IMUNON, visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s periodic reports
and prospectuses filed with the Securities and Exchange Commission.
IMUNON assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
Executive Vice President, CFO |
212-838-3777 |
and Corporate Secretary |
Kgolodetz@lhai.com |
609-482-2455 |
|
jchurch@imunon.com |
|
# # #
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 4 2024 まで 5 2024
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 5 2023 まで 5 2024